期刊
BIOCHEMICAL SOCIETY TRANSACTIONS
卷 46, 期 -, 页码 1449-1462出版社
PORTLAND PRESS LTD
DOI: 10.1042/BST20180136
关键词
-
资金
- Medical Research Council
- Cancer Research UK
- Bayer HealthCare
- Bloodwise
- King's Health Partners Research and Development Fund
- British Council Newton Fund Institutional Links Award
- British Lung Foundation
- Breast Cancer Now
- Experimental Cancer Medicine Centre at King's College London
- King's Health Partners Cancer Research UK Cancer Centre
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust
- King's College London
- MRC [MR/M024733/1] Funding Source: UKRI
Interleukin-6 (IL-6) is a pleiotropic cytokine that activates a classic signalling pathway upon binding to its membrane-bound receptor (IL-6R). Alternatively, IL-6 may ` transsignal' in a manner that is facilitated by its binding to a soluble derivative of the IL-6 receptor (sIL-6R). Resultant signal transduction is, respectively, driven by the association of IL-6/IL-6R or IL-6/sIL-6R complex with the membrane-associated signal transducer, gp130 (Glycoprotein 130). Distinct JAK (Janus tyrosine kinase)/STAT (signal transducers and activators of transcription) and other signalling pathways are activated as a consequence. Of translational relevance, overexpression of IL-6 has been documented in several neoplastic disorders, including but not limited to colorectal, ovarian and breast cancer and several haematological malignancies. This review attempts to summarise our current understanding of the role of IL-6 in cancer development. In short, these studies have shown important roles for IL-6 signalling in tumour cell growth and survival, angiogenesis, immunomodulation of the tumour microenvironment, stromal cell activation, and ultimate disease progression. Given this background, we also consider the potential for therapeutic targeting of this system in cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据